United Therapeutics (UTHR) in Pivotal Point Check: Study Breakthrough in Pulmonary Fibrosis and $2 Billion Buyback Program Drive All-Time High!
Reading Time: 3 minutes
TETON-1 study exceeds expectations: The drug Tyvaso shows significant improvement in lung function in the treatment of idiopathic pulmonary fibrosis. Massive share buyback program: The company has initiated a buyback of its shares worth $2 billion. Analysts raise price targets: Jefferies and Cantor Fitzgerald see further potential up to $668 following the study successes. United Therapeutics, a US biotechnology company focused on rare lung diseases and innovative organ transplantation technologies, made an impressive price...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
